Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 10/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824313 | 0.86 | MEN1 (0.56) | MEN1KMT2AKDM4EKIF11CHUK | |
| SCHEMBL6824483 | 0.78 | MEN1 (0.54) | MEN1KMT2AKDM4EKIF11MAPK1 | |
| SCHEMBL6824452 | 0.76 | MEN1 (0.46) | MEN1KMT2AKDM4EKIF11 | |
| SCHEMBL28207454 | 0.73 | MAP2 (0.47) | MEN1KMT2AKDM4EMAPK1 | |
| SCHEMBL412032 | 0.72 | KIF11 (0.81) | MEN1KMT2AKDM4EKIF11CHUK | |
| SCHEMBL29507666 | 0.72 | KIF11 (0.81) | MEN1KMT2AKDM4EKIF11CHUK | |
| SCHEMBL28207446 | 0.70 | KDM4E (0.50) | MEN1KMT2AKDM4EKIF11MAP2K4 | |
| SCHEMBL17968861 | 0.70 | NR4A2 (0.58) | MEN1KMT2AKDM4EKIF11 | |
| SCHEMBL31706267 | 0.69 | CFTR (0.52) | MEN1KMT2AKDM4EKIF11 | |
| SCHEMBL28025008 | 0.69 | ALOX5 (0.56) | MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | MEN1 3139/4885KMT2A 3944/4885KDM4E 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.